Abstract:Potassium channel tetramerization domain-containing 1 (KCTD1) plays a critical role in transcriptional regulation and adipogenesis, but the significance of KCTD1 in hepatocellular cancer (HCC) has not been reported. In this study, KCTD1 expression is increased in human HCC tissues and closely associated with advanced tumor stages. KCTD1 overexpression enhances HCC growth, migration, and invasion both in vitro and in vivo , while KCTD1 knockdown reverses these effects. Mechanistically, KCTD1 interacts with hypoxia-inducible factor 1 alpha (HIF-1α), enhances HIF-1α protein stability with the inhibited prolyl-hydroxylases (PHD)/Von Hippel-Lindau (VHL) pathway, consequently activating the Vascular Endothelial Growth Factor (VEGF)/VEGFR2 pathway in HCC cells. Sorafenib and KCTD1 knockdown synergistically inhibit intrahepatic tumor growth. miR-129-5p downregulates KCTD1 expression by binding with KCTD1 3′ UTR. Finally, exosomes derived from miR-129-5p-overexpressing HCC cells combine with sorafenib to decrease HCC tumor size. These results suggest that KCTD1 expression protects HIF-1α from degradation and activates the VEGF signaling cascade to enhance HCC progression. Therefore, KCTD1 may serve as a novel target of HCC and pave the way for an efficient combined therapy for advanced human HCC.Funding Information: This work was supported by the National Natural Science Foundation of China (No. 81872256), Key grant of research and development in Hunan Province (No. 2020DK2002), Natural Science Foundation in Hunan Province (NO.2021JJ30453), Key project of Hunan Provincial Education Department (No.19A310), Cooperative Innovation Center of Engineering and New Products for Developmental Biology of Hunan Province (No.20134486), as well as City University of Hong Kong Strategic Research Grant (No. 7005264).Declaration of Interests: These authors declare no competing financial interests.Ethics Approval Statement: This study was approved by the ethical principles and guidelines for Experiments on Animals and HCC tissues of Hunan Normal University (2018-035). Informed consent was gotten from all participants.

Kctd20 Promotes the Development of Non‐small Cell Lung Cancer Through Activating Fak/AKT Pathway and Predicts Poor Overall Survival of Patients

Retracted: KIF20A Silence Inhibits the Migration, Invasion and Proliferation of Non‐small Cell Lung Cancer and Regulates the JNK Pathway

KCTD12 Promotes G1/S Transition of Breast Cancer Cell Through Activating the AKT/FOXO1 Signaling

STK31 Regulates the Proliferation and Cell Cycle of Lung Cancer Cells Via the Wnt/β‑catenin Pathway and Feedback Regulation by C‑myc.

KLHL38 Involvement in Non-Small Cell Lung Cancer Progression Via Activation of the Akt Signaling Pathway.

Upregulation of KIF20A promotes tumor proliferation and invasion in renal clear cell carcinoma and is associated with adverse clinical outcome

Kcnn4 Promotes The Progression Of Lung Adenocarcinoma By Activating The Akt And Erk Signaling Pathways

An evaluation of KIF20A as a prognostic factor and therapeutic target for lung adenocarcinoma using integrated bioinformatics analysis

CDKL3 Promotes Non-small Cell Lung Cancer by Suppressing Autophagy Via Activation of PI3K/Akt/mTOR Pathway.

The overexpression of KIFC1 was associated with the proliferation and prognosis of non-small cell lung cancer.

Upregulation of Δ‐catenin is Associated with Poor Prognosis and Enhances Transcriptional Activity Through Kaiso in Non‐small‐cell Lung Cancer

KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition

KIFC3 promotes the proliferation, migration and invasion of non-small cell lung cancer through the PI3K/AKT signaling pathway

Increased Kif15 Expression Predicts A Poor Prognosis In Patients With Lung Adenocarcinoma

KRT80 Promotes Lung Adenocarcinoma Progression and Serves as a Substrate for VCP

A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer

KIFC3 promotes the progression of non-small cell lung cancer cells through the PI3K/Akt pathway

High Kpnβ1 Expression Promotes Non-Small Cell Lung Cancer Proliferation and Chemoresistance Via the PI3-kinase/AKT Pathway.

Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis

Kctd11 Inhibits Growth and Metastasis of Hepatocellular Carcinoma Through Activating Hippo Signaling

Targeting KCTD1 As a Potential Novel Therapy Ameliorates Hepatocellular Carcinoma Progression Via the HIF-1α/VEGF Pathway